Literature DB >> 23844708

Population health approach for diabetic patients with poor A1C control.

Ted Courtemanche1, Guy Mansueto, Richard Hodach, Karen Handmaker.   

Abstract

BACKGROUND: Diabetes is frequently monitored as part of quality programs and initiatives. The glycated hemoglobin (A1C) test and corresponding values are often used as quality metrics, and patients with values of 9.0% or above (9+) tend to utilize intensive resources. However, this strategy may be missing more profound opportunities to improve quality.
OBJECTIVES: To analyze A1C outcomes in 2 ways: (1) year over year for patients identified as diabetic and (2) from test to test.
METHODS: This study was conducted using data on more than 23,000 patients identified as having diabetes and included A1C laboratory results extracted from electronic medical records.
RESULTS: The percentage of patients with poorly controlled diabetes (9+) is increasing annually, but there is sizable turnover within the population- meaning that new uncontrolled patients replace those whose outcomes improve. More than half (57.5%) of patients have their first 9+ score on their first test. And for those with a prior 9+ result, only 16.8% have 3 consecutive 9+ scores after their initial 9+ test. For all patients, the longer the interval between tests, the greater the probability that the next test result will be 9+.
CONCLUSION: Instead of focusing resources only on the highly dynamic and relatively small subpopulation of patients with 9+ scores, a better option may be ensuring that all patients get regular testing according to appropriate protocols. This total population-based approach would engage all diabetic patients inside and outside practice walls to optimize provider ability to impact health outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23844708

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  5 in total

1.  Food as medicine? Exploring the impact of providing healthy foods on adherence and clinical and economic outcomes.

Authors:  Aleda M H Chen; Juanita A Draime; Sarah Berman; Julia Gardner; Zach Krauss; Joe Martinez
Journal:  Explor Res Clin Soc Pharm       Date:  2022-03-18

2.  Diabetes guidelines may delay timely adjustments during treatment and might contribute to clinical inertia.

Authors:  Augusto Pimazoni-Netto; Maria Teresa Zanella
Journal:  Diabetes Technol Ther       Date:  2014-06-03       Impact factor: 6.118

3.  Type 2 diabetes detection and management among insured adults.

Authors:  Timothy M Dall; Weyna Yang; Pragna Halder; Jerry Franz; Erin Byrne; April P Semilla; Ritashree Chakrabarti; Bruce Stuart
Journal:  Popul Health Metr       Date:  2016-11-21

4.  Estimating the Impact of Novel Digital Therapeutics in Type 2 Diabetes and Hypertension: Health Economic Analysis.

Authors:  Robert J Nordyke; Kevin Appelbaum; Mark A Berman
Journal:  J Med Internet Res       Date:  2019-10-09       Impact factor: 5.428

5.  Diabetes diagnosis and management among insured adults across metropolitan areas in the U.S.

Authors:  Wenya Yang; Timothy M Dall; Eleonora Tan; Erin Byrne; William Iacobucci; Ritashree Chakrabarti; F Ellen Loh
Journal:  Prev Med Rep       Date:  2018-03-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.